Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain
Por:
Garcia, F, Martin-Carbonero, L, Rodriguez, C, Vera, M, del Romero, J, Marcaida, G, Ocete, MD, Caballero, E, Aguilera, A, Benito, R, de Lejarazu, RO, Rojo, S, Eiros, JM, Ramos, C, Garcia, J, Paz, I, Trigo, M, Diz, J, Garcia-Campello, M, Rodriguez-Iglesias, M, Hernandez-Betancor, A, Martin, AM, Ramos, JM, Gimeno, A, Sanchez, V, Gomez-Hernando, C, Cilla, G, Perez-Trallero, E, Fernandez-Pereira, L, Niubo, J, Hernandez, M, Lopez-Lirola, AM, Gomez-Sirvent, JL, Force, L, Cabrera, J, Perez, S, Morano, L, Raya, C, Gonzalez-Praetorius, A, Cifuentes, C, Penaranda, M, Nieto, MC, Montejo, JM, Roc, L, Viciana, I, Lozano, AB, Fernandez-Fuertes, E, Fernandez, JM, Garcia-Bermejo, I, Gaspar, G, Tellez, R, Gorgolas, M, Diaz, J, Miralles, P, Perez, L, Valeiro, M, Aldamiz, T, Margall, N, Suarez, A, Rodriguez-Avial, I, Requena, S, Benitez-Gutierrez, L, Cuervas-Mons, V, de Mendoza, C, Barreiro, P, Soriano, V
Publicada:
1 may 2019
Resumen:
Background: HIV-2 is a neglected virus despite estimates of 1-2 million people being infected worldwide. The virus is naturally resistant to some antiretrovirals used to treat HIV-1 and therapeutic options are limited for patients with HIV-2.
Methods: In this retrospective observational study, we analysed all HIV-2-infected individuals treated with integrase strand transfer inhibitors (INSTIs) recorded in the Spanish HIV-2 cohort. Demographics, treatment modalities, laboratory values, quantitative HIV-2 RNA and CD4 counts as well as drug resistance were analysed.
Results: From a total of 354 HIV-2-infected patients recruited by the Spanish HIV-2 cohort as of December 2017, INSTIs had been given to 44, in 18 as first-line therapy and in 26 after failing other antiretroviral regimens. After a median follow-up of 13 months of INSTI-based therapy, undetectable viraemia for HIV-2 was achieved in 89% of treatment-naive and in 65.4% of treatment-experienced patients. In parallel, CD4 gains were 82 and 126 cells/mm(3), respectively. Treatment failure occurred in 15 patients, 2 being treatment-naive and 13 treatment-experienced. INSTI resistance changes were recognized in 12 patients: N155H (5), Q148H/R (3), Y143C/G (3) and R263K (1).
Conclusions: Combinations based on INSTIs are effective and safe treatment options for HIV-2-infected individuals. However, resistance mutations to INSTIs are selected frequently in failing patients, reducing the already limited treatment options.
Filiaciones:
Garcia, F:
Hosp Univ San Cecilio, Inst Invest Ibs, Granada, Spain
Martin-Carbonero, L:
Hosp Univ La Paz, Madrid, Spain
Rodriguez, C:
Ctr Sanitario Sandoval, Madrid, Spain
Vera, M:
Ctr Sanitario Sandoval, Madrid, Spain
del Romero, J:
Ctr Sanitario Sandoval, Madrid, Spain
Marcaida, G:
Hosp Gen Univ, Valencia, Spain
Ocete, MD:
Hosp Gen Univ, Valencia, Spain
Caballero, E:
Hosp Vall dHebro, Barcelona, Spain
Hosp Valle De Hebron, Barcelona, Spain
Aguilera, A:
Hosp Conxo CHUS, Santiago, Spain
Benito, R:
Hosp Clin Univ Lozano Blesa, Zaragoza, Spain
de Lejarazu, RO:
Hosp Clin Univ, Valladolid, Spain
Rojo, S:
Hosp Clin Univ, Valladolid, Spain
Eiros, JM:
Hosp Rio Hortega, Valladolid, Spain
Ramos, C:
Hosp Rio Hortega, Valladolid, Spain
Garcia, J:
Hosp Cristal Pinor, Orense, Spain
Paz, I:
Hosp Cristal Pinor, Orense, Spain
Trigo, M:
Complejo Hosp, Pontevedra, Spain
Diz, J:
Complejo Hosp, Pontevedra, Spain
Garcia-Campello, M:
Complejo Hosp, Pontevedra, Spain
Rodriguez-Iglesias, M:
Hosp Univ, Puerto Real, Spain
Hernandez-Betancor, A:
Hosp Insular Hosp Univ, Las Palmas Gran Canaria, Spain
Martin, AM:
Hosp Insular Hosp Univ, Las Palmas Gran Canaria, Spain
Ramos, JM:
Hosp Univ, Alicante, Spain
Gimeno, A:
Hosp Univ, Alicante, Spain
Sanchez, V:
Hosp Gen, Elche, Spain
Gomez-Hernando, C:
Complejo Hosp Virgen Salud, Toledo, Spain
Cilla, G:
Hosp Donostia, San Sebastian, Spain
Perez-Trallero, E:
Hosp Donostia, San Sebastian, Spain
Fernandez-Pereira, L:
Hosp San Pedro de Alcantara, Caceres, Spain
Niubo, J:
Ciudad Sanitaria Bellvitge, Barcelona, Spain
Hernandez, M:
Hosp Univ La Laguna, Tenerife, Spain
Lopez-Lirola, AM:
Hosp Univ La Laguna, Tenerife, Spain
Gomez-Sirvent, JL:
Hosp Univ La Laguna, Tenerife, Spain
Force, L:
Hosp Gen, Mataro, Spain
Cabrera, J:
Hosp Meixoeiro, Vigo, Spain
Perez, S:
Hosp Meixoeiro, Vigo, Spain
Morano, L:
Hosp Meixoeiro, Vigo, Spain
Raya, C:
Hosp Bierzo, Ponferrada, Spain
Gonzalez-Praetorius, A:
Hosp Univ, Guadalajara, Spain
Cifuentes, C:
Hosp Son Espases, Mallorca, Spain
Penaranda, M:
Hosp Son Espases, Mallorca, Spain
Nieto, MC:
Hosp Basurto, Bilbao, Spain
Montejo, JM:
Hosp Cruces, Bilbao, Spain
Roc, L:
Hosp Miguel Servet, Zaragoza, Spain
Viciana, I:
Hosp Virgen de la Victoria, Malaga, Spain
Lozano, AB:
Hosp Poniente, Almeria, Spain
Fernandez-Fuertes, E:
Hosp Poniente, Almeria, Spain
Fernandez, JM:
Hosp Poniente, Almeria, Spain
Garcia-Bermejo, I:
Hosp Univ, Getafe, Spain
Gaspar, G:
Hosp Univ, Getafe, Spain
Tellez, R:
Fdn Jimenez Diaz, Madrid, Spain
Gorgolas, M:
Fdn Jimenez Diaz, Madrid, Spain
Miralles, P:
Hosp Univ Gregorio Maranon, Madrid, Spain
Perez, L:
Hosp Gregorio Maranon, Madrid, Spain
Valeiro, M:
Hosp Gregorio Maranon, Madrid, Spain
Aldamiz, T:
Hosp Gregorio Maranon, Madrid, Spain
Margall, N:
Hosp Santa Creu & Sant Pau, Barcelona, Spain
Suarez, A:
Hosp Clin San Carlos, Madrid, Spain
Rodriguez-Avial, I:
Hosp Clin San Carlos, Madrid, Spain
Requena, S:
Puerta de Hierro Univ Hosp & Res Inst, Madrid, Spain
IIS Hosp Univ Puerta de Hierro, Majadahonda, Spain
Benitez-Gutierrez, L:
IIS Hosp Univ Puerta de Hierro, Majadahonda, Spain
Cuervas-Mons, V:
IIS Hosp Univ Puerta de Hierro, Majadahonda, Spain
de Mendoza, C:
Puerta de Hierro Univ Hosp & Res Inst, Madrid, Spain
Univ San Pablo CEU, Madrid, Spain
IIS Hosp Univ Puerta de Hierro, Majadahonda, Spain
Barreiro, P:
Hosp Univ La Paz, Madrid, Spain
Soriano, V:
Hosp Univ La Paz, Madrid, Spain
UNIR Hlth Sci Sch, Madrid, Spain
Green Accepted
|